|
Myriad announces commercial agreement with
RainDance Technologies
04-18-2013
EDIT CONNECT
SHARING OPTIONS:
SALT LAKE CITY—Myriad Genetics and Lexington, Mass.-based
RainDance Technologies, a company that specializes in digital biology with
droplet-based technology, have announced the establishment of a new commercial
agreement. Under this deal, Myriad will adopt RainDance's ThunderStorm
Target
Enrichment System for Myriad's next-generation sequencing-based Hereditary
Cancer Panel (HCP) test. In conjunction with the commercial
agreement, the two
companies have also signed a multi-year supply agreement under which RainDance
will provide Myriad with ThunderStorm systems,
reagents, gene panels and
consumables.
"Myriad's selection of our ThunderStorm System for their
HCP
test, one of the most significant commercial opportunities in their product
portfolio, validates our product differentiation and innovative
technology with
one of the most exacting clinical sequencing customers in the world," Roopom
Banerjee, president and CEO of RainDance, said in a press
release. "The Myriad
relationship builds on our proven track record with more than 70 major genetic
and translational research labs worldwide. With
our proprietary platform,
Myriad is establishing a new industry standard for next-generation sequencing
of cancer and inherited disease."
The ThunderStorm system from RainDance uses a proprietary
single-molecule droplet technology for sequence
enrichment, which provides
users with the ability to target up to 20,000 regions of the genome with any
commercially available next-generation
sequencing platforms. Myriad is seeking
to integrate RainDance's technology into its own next-generation HCP test,
which can be used to assess highly
significant genes that are known to play
pivotal roles in inherited cancer risk.
"We are excited to
announce this strategic relationship with
RainDance Technologies as it marks an important milestone in our preparation
for the future launch of our
next-generation HCP test," Mark Capone, president
of Myriad Genetics Laboratories, commented in a statement. "The ThunderStorm
System offers Myriad
unparalleled genomic coverage, the ability to detect large
gene rearrangements, workflow benefits and a favorable cost profile, all of
which have been
critical in overcoming the challenges associated with creating
content-rich next-generation sequencing gene panels suitable for a
high-throughput
commercial laboratory."
The agreement comes just under a month after Myriad
announced a
commercial partnership with PharmaMar, a leading developer of
marine-derived drugs. Per the agreement, Myriad will conduct homologous
recombination deficiency (HRD) testing on patients enrolled in PharmaMar's
Phase II clinical study of PM1183, a drug candidate that causes double-stranded
DNA breaks that lead to apoptosis, or cell death. The partners hope that
by
examining HRD status in patients treated with PM1183 in the study, they will be
able to learn more about the connection between HRD status and
PM1183 response.
No financial details for the agreement were disclosed.
SOURCE: Myriad press release Code: E04181301 Back |
Home |
FAQs |
Search |
Submit News Release |
Site Map |
About Us |
Advertising |
Resources |
Contact Us |
Terms & Conditions |
Privacy Policy
|